2022
Anastomosing Hemangioma of the Ovary With Leydig Cell Hyperplasia: A Clinicopathologic Study of 12 Cases
McHenry A, Buza N. Anastomosing Hemangioma of the Ovary With Leydig Cell Hyperplasia: A Clinicopathologic Study of 12 Cases. International Journal Of Gynecological Pathology 2022, 42: 167-175. PMID: 35512214, DOI: 10.1097/pgp.0000000000000887.Peer-Reviewed Original ResearchConceptsLeydig cell hyperplasiaAnastomosing hemangiomaLeydig cellsCell hyperplasiaEndothelial cellsHobnail endothelial cellsSymptomatic pelvic massSteroid cell tumorTime of resectionMultiple anatomic sitesFemale genital tractLeydig cell tumorMale genitourinary tractGlobular intracytoplasmic inclusionsHormonal manifestationsClinicopathologic studyPatient agePelvic massOvarian hilumGenitourinary tractLuteinized cellsCell tumorsVascular neoplasmVascular proliferationGenital tract
2021
Immunohistochemistry
Euscher E, Buza N, Hui P. Immunohistochemistry. Practical Anatomic Pathology 2021, 367-416. DOI: 10.1007/978-3-030-68608-6_15.Peer-Reviewed Original ResearchFemale genital tractGynecologic tractGynecologic tumorsHistologic featuresRare tumorPatient prognosisGenital tractTumor alterationsUseful adjunctPrimary siteTumor typesPossible treatmentImmunohistochemistryTumorsSame organDiagnostic toolProper classificationTractCurrent useTreatmentBroad spectrumPrognosisTherapySubtypesAdjunct
2019
HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapy
Rottmann D, Snir OL, Wu X, Wong S, Hui P, Santin AD, Buza N. HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapy. Modern Pathology 2019, 33: 118-127. PMID: 31477811, DOI: 10.1038/s41379-019-0358-x.Peer-Reviewed Original ResearchConceptsEndometrial serous carcinomaHER2-positive tumorsSerous carcinomaSarcoma componentHER2 statusGynecologic carcinosarcomaHER2 expression/amplificationRecent phase II clinical trialPhase II clinical trialCarboplatin-paclitaxel chemotherapyEquivocal HER2 expressionProgression-free survivalAppropriate patient selectionExpression/amplificationFemale genital tractMembranous staining patternHER2 protein expressionHER2 immunohistochemical scoresUterine primaryDismal prognosisPatient selectionCarcinoma componentMixed carcinomasHER2 expressionClinical trials